Changes in HbA(1c) and frequency of measuring HbA(1c) and adjusting glucose-lowering medications in the 10 years following diagnosis of type 2 diabetes: a population-based study in the UK
Artikel i vetenskaplig tidskrift, 2014

Aim/hypothesis The aim of this work was to study levels of HbA(1c) and patterns of adjusting glucose-lowering drugs in patients with impaired glycaemic control over 10 years after diagnosis of type 2 diabetes. Methods We studied 4,529 individuals in The Health Improvement Network Database newly diagnosed with type 2 diabetes in the year 2000. Results From 6 months to 10 years after diagnosis, the HbA(1c) increased from 7.04% (53.4 mmol/mol) to 7.49% (58.3 mmol/mol) (average annual change: 0.047% [0.51 mmol/mol]). The greatest annual change occurred between 6 months and 2 years (0.21% [2.30 mmol/mol] increase per year, p < 0.001), followed by the 2-5 year time period (0.033% [0.36 mmol/mol] increase per year, p < 0.001). No significant increase in HbA(1c) occurred between 5 and 10 years (p = 0.20). In multivariable analyses, patients who were younger (p < 0.001), with higher BMI (p = 0.033) and who were current insulin users (p = 0.024) at diagnosis had greater increases in HbA(1c) between 6 months and 2 years. For individuals with HbA(1c) above 7.0% (53 mmol/mol) the mean time to next measurement of HbA(1c) was 0.53 years and increase in doses or changes to other glucose-lowering medications were performed in 26% of cases. Conclusions/interpretation HbA(1c) increases by approximately 0.5% (5 mmol/mol) over 10 years after diagnosis of type 2 diabetes, with the main increase appearing in the first years after diagnosis. More frequent monitoring of HbA(1c) and adjustments of glucose-lowering drugs may be essential to prevent the decline.

MORTALITY

Type 2 diabetes

HbA(1c)

HEALTH

OUTCOMES

RISK

METFORMIN

PREVALENCE

COMPLICATIONS

Endocrinology & Metabolism

MELLITUS

PRIMARY-CARE

TRENDS

Medication

Författare

Marcus Lind

Göteborgs universitet

A. Pivodic

Statistiska Konsultgruppen

L. Cea-Soriano

Centro Espanol de Investigacion Farmacoepidemiologica

Olle Nerman

Göteborgs universitet

Chalmers, Matematiska vetenskaper, matematisk statistik

N. G. Pehrsson

Statistiska Konsultgruppen

L. A. Garcia-Rodriguez

Centro Espanol de Investigacion Farmacoepidemiologica

Diabetologia

0012-186X (ISSN) 1432-0428 (eISSN)

Vol. 57 1586-1594

Ämneskategorier

Endokrinologi och diabetes

DOI

10.1007/s00125-014-3250-8